State of morphofunctional parameters of left ventricle and indicators of endothelial dysfunction in patients with hypertension in combination with COPD on background of cytoprotective therapy

One of the directions of clinical medicine is to study the effect of concomitant diseases of the bronchopulmonary system on the prognosis of diseases of the cardiovascular system.

Objective - to evaluate the state of a number of morphofunctional parameters of the cardiovascular system and endothelial dysfunction in patients with hypertension in combination with COPD on the background of cytoprotective therapy.

Materials and methods. The study included a group of patients (80 people) with hypertension, some patients (40 people) had moderate or severe chronic obstructive pulmonary disease in combination with hypertension (FEV1/FVC <0.7 (70%), FEV1<80% of the required). The age of the patients participating in the study, he ranged from 35 to 67 years old. The average age was 48.3±1.1 years. The hypertensive history of the persons under observation ranged from 4 to 17 years, the average duration of the disease was 8.3±1.2 years.

Results. The article analyzes changes in a number of morphofunctional parameters of the cardiovascular system and endothelial dysfunction in patients with hypertension in combination with chronic obstructive pulmonary disease on the background of cytoprotective therapy. In patients with hypertension in combination with COPD, a more pronounced deviation from the norm of indicators characterizing the morphofunctional state of the cardiovascular system and endothelial function was revealed.

Conclusion. The use of mildronate in combination with traditional therapy in patients with hypertension has a positive effect on the condition of the heart and blood vessels. In the presence of chronic obstructive pulmonary disease in combination with arterial hypertension, the positive effect of mildronate is more pronounced.

1. Zafiraki V.K., Skaletsky K.V., Namitokov A.M., Shulzhenko L.V., Kosmacheva E.D., Pershukov I.V. Prediction of long-term adverse cardiovascular events after percutaneous coronary interventions in patients with coronary artery disease and concomitant chronic obstructive pulmonary disease. Kardiologiia. 2020;60(5):115-122 (in Russ.). DOI: 10.18087/cardio.2020.5.n1020. EDN: BKBRRR

2. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.P., et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI: 10.1093/eurheartj/ehy394.

3. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R.F., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. DOI: 10.1093/eurheartj/ehz425.

4. de Miguel Díez J., Chancafe Morgan J., Jiménez García R. The association between COPD and heart failure risk: a review.Int J Chron Obstruct Pulmon Dis. 2013;8:305-312. DOI: 10.2147/COPD.S31236.

5. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798-807. DOI: 10.1378/chest.12-0938.

6. O’Donnell D.E., Webb K.A., Neder J.A. Lung hyperinflation in COPD: applying physiology to clinical practice. COPD Res Pract. 2015;1:4. DOI: 10.1186/s40749-015-0008-8.

7. Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-139. DOI: 10.1093/eurjhf/hfn013.

8. Grigor'eva N.Yu., Kuznetsov A.N., Sharabrin E.G. The place of chronic obstructive pulmonary disease in the development of the cardiovascular continuum. Serdtse: zhurnal dlya praktikuyushchikh vrachey. 2012;2(64):120-122 (in Russ.). EDN: PNBQNB.

9. Choudhury G., Rabinovich R., MacNee W.Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):101-130. DOI: 10.1016/j.ccm.2013.10.007.

10. Patel A.R., Patel A.R., Singh S., Singh S., Khawaja I. Global Initiative for Chronic Obstructive Lung Disease: The Changes Made. Cureus. 2019;11(6):e4985. DOI: 10.7759/cureus.4985.

11. Zafiraki V.K., Kosmacheva E.D., Shulzhenko L.V., Kizhvatova N.V., Nemtsova E.A., Pershukov I.V. Kardiologiia. 2020;60(9):84-91 (in Russ.). DOI: 10.18087/cardio.2020.9.n1263. EDN: NCNQZW.

12. Chuchalin A.G. White Paper: Pulmonology. Pul'monologiya. 2004;(1):7-34 (in Russ.)

13. Shpagina L.A., Gerasimenko O.N., Shpagin I.S., Zueva M.A. Endothelial dysfunction and vascular remodeling in hypertension combined with chronic obstructive pulmonary disease: new therapeutic targets. Pul'monologiya. 2009;(3):47-54 (in Russ.). EDN: KNVKHD.

14. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-1519. DOI: 10.1161/01.cir.0000056767.69054.b3.

15. Martynov A.I., Tanashyan M.M., Malyavin A.G., Bogolepova A.N., Borovkova N.Yu., Eliseeva L.N., Zhuravleva M.V., Zakharov V.V., et al. Resolution of the expert council "possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders". Therapy. 2023;9(10):148-158 (in Russ.). DOI: 10.18565/therapy.2023.10.148-158. EDN: TZWYWX.

16. Avdeev S.N., Baymakanova G.E. Management strategy for a cardiological patient suffering from COPD. Cardio-pulmonological relationships. Serdtse: zhurnal dlya praktikuyushchikh vrachey. 2007;6(6):305-309 (in Russ.). EDN: ODSVDZ.

17. Kuznetsov A.N., Grigoryeva N.Yu., Sharabrin E.G. Importance of early diagnostics of chronic obstructive pulmonary disease in patients with coronary heart disease. Cardiovascular therapy and prevention. 2011;10(3):47-50 (in Russ.). DOI: 10.15829/1728-8800-2011-3-47-50. EDN: NQZWSF.

18. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., Hawthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711-715. DOI: 10.1136/bmj.313.7059.711.

19. Nedogoda S.V., Chalyabi T.A., Barykina I.N., Ledyaeva A.A., Mazina G.G., Chumachek E.V., Tsoma V.V., Salasuk A.S., et al. Vascular rigidity and velocity of pulse wave propagation as bridgehead and target for pharmacotherapy. Journal of Volgograd State Medical University. 2012;(1):113-116 (in Russ.). EDN: OWTYZP.

20. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., Ducimetiere P., Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236-1241. DOI: 10.1161/01.hyp.37.5.1236.

21. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-2678. DOI: 10.1161/hc4601.099485.

22. Lüscher T.F., Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis. 1995;118 Suppl:S81-90.

23. van Suylen R.J., Smits J.F., Daemen M.J. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1423-1428. DOI: 10.1164/ajrccm.157.5.9709050.

24. Geltser B.I., Brodskaya T.A., Nevzorova V.A. Estimation of arterial stiffness in patients with chronic obstructive pulmonary disease. Pul'monologiya. 2008;(1):45-50 (in Russ.). EDN: ISFNCN.

25. Ovcharenko S.I., Nersesian Z.N. Systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with hypertension: review of the literature and our own data. Consilium Medicum. 2015;17(11):8-12 (in Russ.). EDN: VIIXNB.

26. Sabit R., Bolton C.E., Edwards P.H., Pettit R.J., Evans W.D., McEniery C.M., Wilkinson I.B., Cockcroft J.R., et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259-1265. DOI: 10.1164/rccm.200701-067OC.

27. Mikhin V.P. Cytoprotection in cardiology: achievements and prospects. Kardiologiia. 2015;55(10):90-95 (in Russ.). DOI: 10.18565/cardio.2015.10.90-95. EDN: UYHOLX.

28. Mareev V.Yu., Ageev F.T., Arutyunov G.P., Koroteev A.V., Mareev Yu.V., Ovchinnikov A.G., Belenkov Yu.N., Vasyuk Yu.A., et al. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). Approved at the SEHF congress on December 7, 2012, at the SEHF board of directors meeting on March 31, 2013, and at the RSC congress on September 25, 2013.Russian heart failure journal. 2013;14(7):379-472 (in Russ.). EDN: VHDBDT.

29. Statsenko M.E., Turkina S.V., Lopushkova Yu.E., Kosivtsova M.A. New treatment options for a patient with chronic heart failure and chronic obstructive pulmonary disease. Medical council. 2022;16(6):87-97 (in Russ.). DOI: 10.21518/2079-701X-2022-16-6-13-22. EDN: PSWLDB.

30. Arterial hypertension in adults. Clinical recommendations (approved by the Ministry of Health of Russia in 2020) (in Russ.). URL: https://cr.minzdrav.gov.ru/recomend/62

31. Mancia G., Kreutz R., Brunström M., Burnier M., Grassi G., Januszewicz A., Muiesan M.L., Tsioufis K., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12): 1874-2071. DOI: 10.1097/HJH.0000000000003480.

32. Mikhin V.P., Pozdnyakov Yu.M., Khlebodarov F.E., Koltsova O.N. Mildronate in cardiology practice - current evidence, ongoing research, and future perspectives. Cardiovascular therapy and prevention. 2012;11(1):96-103 (in Russ.). DOI: 10.15829/1728-8800-2012-1-96-103. EDN: RCKGTF.

33. Mikhin V.P., Khlebodarov F.E. Mildronate potential in patients with cardiovascular disease.Russian journal of cardiology. 2010;15(4):83-92 (in Russ.). EDN: MUENKZ.

34. Mikhin V.P., Khlebodarov F.E., Vasil'eva D.A., Gromnatskii N.I. Mildronate use in complex treatment of arterial hypertension in patients with ischemic heart disease and its influence on heart and vessels morphofunctional state. Consilium Medicum. 2019;21(12):68-73 (in Russ.). DOI: 10.26442/20751753.2019.12.190699. EDN: AEWKXG.